King Wealth Management Group lifted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 84.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,750 shares of the medical equipment provider's stock after acquiring an additional 6,750 shares during the period. King Wealth Management Group's holdings in Hologic were worth $1,063,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in HOLX. General Partner Inc. purchased a new position in shares of Hologic in the fourth quarter valued at $26,000. Venturi Wealth Management LLC boosted its stake in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the period. First Horizon Advisors Inc. boosted its stake in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 134 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on HOLX shares. Stephens reiterated an "overweight" rating and set a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. William Blair reiterated an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Citigroup reduced their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Leerink Partners downgraded shares of Hologic from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Finally, Needham & Company LLC downgraded shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target on the stock. in a research report on Monday, February 3rd. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Hologic has a consensus rating of "Hold" and a consensus target price of $84.62.
Check Out Our Latest Analysis on Hologic
Hologic Price Performance
Hologic stock traded up $0.16 during trading hours on Tuesday, hitting $61.98. 3,766,525 shares of the company traded hands, compared to its average volume of 1,712,542. The firm has a market cap of $13.91 billion, a P/E ratio of 19.55, a P/E/G ratio of 2.14 and a beta of 0.97. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm's 50-day simple moving average is $66.94 and its two-hundred day simple moving average is $74.51. Hologic, Inc. has a 1-year low of $59.55 and a 1-year high of $84.67.
Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.
About Hologic
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Further Reading
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
